Depatuxizumab alfa, formerly referred to as ABT-806, represents a novel humanized immunoglobulin targeting the VN associating domain. This therapeutic agent is designed to disrupt the formation of the https://bookmark-dofollow.com/story29321276/depatuxizumab-alfa